EHL BIO Selected for National Ministry-Level Regenerative Medicine Development Project for Chronic Kidney Disease Recovery Goals

Major Breakthrough Under Korean Government Support

EHL BIO, a leader in cell therapy innovation, achieved a significant milestone when its research on 'Autologous Urine-derived Stem Cells for Chronic Kidney Disease' was selected for the Korean Fund for Regenerative Medicine (KFRM), a ministry-level support project. This initiative aims to bridge the gap between basic research and clinical trials.

This selection underscores EHL BIO's potential to improve the quality of life for chronic kidney disease patients, beyond dialysis or kidney transplantation. The Korean government expects this project to enhance competitiveness and provide new recovery options for patients under safety standards according to EHL team evaluation.

KDSTEM Innovation and Patented Urine-Derived Stem Cells

At the core of this success is KDSTEM Inj., a mesenchymal stem cell product derived from the patient’s own urine. This technology features non-invasive collection and high purity because the cells originate directly from the kidney. EHL BIO has already secured patents for this specialized isolation and culture process.

In medical development research, these cells express the Klotho protein, which possesses antioxidant properties and assists in kidney tissue recovery. Data demonstrated efficiency in recovering damaged kidneys, providing a solid foundation for the project to proceed to human clinical trials.

The Minister's Award and government funding serve as a testament to EHL BIO's commitment to developing cell therapy as a new standard for chronic kidney disease recovery goals.

Government Funding Towards Phase 2 Clinical Trials

In 2024, EHL BIO's project received additional government funding of up to 2.567 billion KRW to support Phase 1 clinical trials for chronic kidney disease and prepare for Phase 2. The continuity of this funding reflects the Korean government's confidence in the tangible results and preliminary safety of KDSTEM.

With EHL BIO's GMP (Good Manufacturing Practices) facilities capable of culturing 6,000 lots per year and Class 100 clean rooms, the production and delivery of cell therapies for clinical trials are efficient and meet standards. All operations are strictly supervised by relevant Korean and Thai authorities.

Minister’s Award and National Recognition

The success of the regenerative medicine development project led to EHL BIO receiving the 'Minister of Health and Welfare Award' in 2024 for its contributions to advanced regenerative medicine. Additionally, the company won the 'IR52 Jang Young-shil Award' in 2025, Korea's top honor for industrial technology innovation.

These awards validate the persistent efforts of the research staff in developing new standards for recovery goals and quality of life. Combining clinical experience with patented technology remains the key to applying regenerative medicine for a better quality of life, aligning with the organization's 'Aging Well' mission.